NCT05617222

Brief Summary

Loss of muscle mass is common phenotypic trait of muscular disuse and ageing. The loss of muscle mass affects, among others, the ability to maintain homeostasis of glucose metabolism and the energy reservoir in catabolic conditions, while also affecting mechanical muscle function which can cause detrimental impairments in general functional status and hence quality of life. However, a limited amount of research has attempted to elucidate molecular regulators of muscle mass loss following bed rest in older individuals and across genders. Consequently, the mechanistic drivers are unresolved and there are currently no effective therapeutic strategies to counteract muscle wasting and loss of function in individuals submitted to bed rest e.g. during hospitalization. Purpose The purpose is to examine the effects of 5 days of bed rest on muscle mass, including myofibrillar protein synthesis and breakdown, and muscle function, and elucidate molecular regulators of muscle mass loss and metabolic pathways, while also investigating if potential negative effects can be counteracted by daily NeuroMuscular Electrical Stimulation (NMES) across different age and genders. Methods The study is designed as a randomized controlled cross-over 5-day bed rest study including a group of healthy young (18-30 years) and healthy old (65-80 years) men and women. Participants will receive daily electrical stimulation (NMES) of the thigh muscles (30 min x 3/day) on one leg (ES), while the other leg serves as a control (CON). Participants will be tested at baseline (pre) and after (post) intervention for muscle strength, muscle power, balance, and muscle activation. Blood samples are collected at several time points and muscle biopsies are sampled pre- and post-intervention along with assessment of whole-body muscle mass and thigh muscle mass. Scientific exposition The results from the study can potentially provide insight into the adaptive mechanisms associated with NMES training and muscular disuse on both cellular- and whole-body level. The understanding of the underlying mechanisms is crucial for the application of NMES in a therapeutic context and will furthermore help us understand the basic mechanism regulating the skeletal muscle mass during both training and muscular disuse. Overall, the results can potentially help establishing treatments to counteract loss of muscle mass, muscle function and muscle health during periods of muscular disuse.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 29, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 22, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 15, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2023

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2024

Completed
Last Updated

November 15, 2022

Status Verified

November 1, 2022

Enrollment Period

10 months

First QC Date

August 22, 2022

Last Update Submit

November 14, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in Myofiber cross-sectional area

    Histochemical analysis of type I and type II myofiber cross-sectional area

    Change from baseline after bed rest intervention

  • Assessment of myofibrillar protein synthesis

    Quantification of myofibrillar protein synthesis using the stable-isotope amino acid tracer deuterium oxide (D2O)

    Assessed during the period from pre-intervention biopsies (day 0, first day of bed rest) to post-intervention biopsies (day 5, last day and cessation of bed rest)

  • Change in maximal isometric muscle strength and superimposed twitch

    Maximal isometric voluntary quadriceps strength combined with the superimposed twitch technique to assess maximal strength and voluntary muscle activation

    Change from baseline after bed rest intervention

Secondary Outcomes (12)

  • Change in total Akt protein assessed by Western blot

    Change from baseline after bed rest intervention

  • Change in total mTOR protein assessed by Western blot

    Change from baseline after bed rest intervention

  • Change in total MuRF-1 protein assessed by Western blot

    Change from baseline after bed rest intervention

  • Change in total Atrogin-1 protein assessed by Western blot

    Change from baseline after bed rest intervention

  • Change in total myostatin protein assessed by Western blot

    Change from baseline after bed rest intervention

  • +7 more secondary outcomes

Other Outcomes (2)

  • Accelerometer data

    3 days prior to the intervention

  • Accelerometer data

    Throughout the 5 day intervention

Study Arms (2)

Bed rest- Control

ACTIVE COMPARATOR

One leg will be subjected to disuse by bed rest and will not receive further treatment during the bed rest period.

Other: Bed rest

Bed rest + NMES

EXPERIMENTAL

One leg will be subjected to disuse by bed rest and will in addition receive neuromuscular electrical stimulation of the quadriceps muscle 3 times/day.

Other: Bed restOther: Neuromuscular electrical stimulation

Interventions

5 days of strict bed rest

Bed rest + NMESBed rest- Control

Unilateral neuromuscular electrical stimulation (m. Quadriceps)

Bed rest + NMES

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy
  • Age between 18-30 or 65-80 years
  • Injury free in the lower extremities (No previous or current knee injuries or knee pain)
  • Normal weight
  • Consumes normal diet

You may not qualify if:

  • Cognitive impairment affecting the ability to participate in the study.
  • Health related contraindications to participating in the intervention (i.e., bed rest and/or NMES), such as eczema and rash on the lower extremities
  • Smoker
  • Obesity
  • Not able to speak or understand Danish.
  • Acute or chronic diseases such as diabetes, cancer, embolism, infection, cardio-vascular diseases
  • Use of medication which affects myofibrillar protein synthesis or the skeletal muscle tissue
  • Use of other medication (e.g. anticoagulants, adrenal cortex hormone \[within the last 3 months\] etc.)
  • Previous or current use of anabolic steroids
  • Previous participation in research trials involving deuterium oxide or another stable isotope tracer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bispebjerg Hospital

Copenhagen, 2400, Denmark

RECRUITING

MeSH Terms

Conditions

Muscular Disorders, Atrophic

Interventions

Bed Rest

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Charlotte Suetta, Professor

    Bispebjerg Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The assessors will be without knowledge of which leg has received neuromuscular electrical stimulation and which leg was control
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Participants are subjected to 5 days bed rest. One leg will receive 3/daily neuromuscular electrical stimulation. The contralateral leg will serve as control-leg undergo disuse only.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Dr.Med

Study Record Dates

First Submitted

August 22, 2022

First Posted

November 15, 2022

Study Start

April 29, 2022

Primary Completion

February 28, 2023

Study Completion

August 1, 2024

Last Updated

November 15, 2022

Record last verified: 2022-11

Locations